{"id":"npc-01","safety":{"commonSideEffects":[{"rate":"0.1-1.0%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1.0-5.0%","effect":"Increased risk of genital yeast infections"},{"rate":"5.0-10.0%","effect":"Increased risk of hypotension"},{"rate":"0.1-1.0%","effect":"Increased risk of acute kidney injury"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NPC-01 works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. By reducing glucose reabsorption, NPC-01 also has a diuretic effect, which can help reduce blood pressure.","oneSentence":"NPC-01 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:34.688Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"trialDetails":[{"nctId":"NCT01246791","phase":"PHASE3","title":"Pharmacokinetics of NPC-01 After Single Oral Administration in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2010-11","conditions":"Healthy","enrollment":12},{"nctId":"NCT00902746","phase":"PHASE3","title":"Efficacy and Safety, Long-Term Study of NPC-01 to Treat Dysmenorrhea Associated With Endometriosis","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2009-05","conditions":"Dysmenorrhea","enrollment":149},{"nctId":"NCT01253824","phase":"PHASE3","title":"Pharmacodynamics of NPC-01/IKH-01; Effect of NPC-01/IKH-01 on Sexual Hormone Concentrations in Healthy Female Volunteers","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2011-01","conditions":"Healthy","enrollment":14},{"nctId":"NCT01129102","phase":"PHASE3","title":"Efficacy and Safety Study of NPC-01 to Treat Dysmenorrhea","status":"COMPLETED","sponsor":"Nobelpharma","startDate":"2010-05","conditions":"Dysmenorrhea","enrollment":215}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["norethisterone and ethinyl estradiol","Norethisterone and Ethinyl Estradiol"],"phase":"phase_3","status":"active","brandName":"NPC-01","genericName":"NPC-01","companyName":"Nobelpharma","companyId":"nobelpharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NPC-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}